Aulos Bioscience
Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), an AI-designed monoclonal antibody that redirects IL-2 toward anti-tumor immune activation while avoiding Treg expansion and IL-2 toxicities, currently in Phase 2 trials for solid tumors.
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aulos Bioscience does
Aulos Bioscience is a privately held, clinical-stage immuno-oncology company developing imneskibart (AU-007), a human IgG1 monoclonal antibody computationally designed by co-founder Biolojic Design to selectively bind the CD25-binding portion of interleukin-2 (IL-2). By occupying this epitope, imneskibart redirects endogenous IL-2 toward effector T cells and NK cells while preventing IL-2 from engaging trimeric receptors on regulatory T cells, the vasculature, and pulmonary endothelium — thereby avoiding the vascular leak syndrome and pulmonary edema that have historically limited high-dose IL-2 therapy. The drug is administered as an outpatient regimen with a half-life exceeding 19 days, enabling bi-weekly dosing.
The company is conducting a Phase 1/2 clinical trial (NCT05267626) at sites in the United States and Australia, evaluating imneskibart as monotherapy and in combination with low-dose subcutaneous aldesleukin, nivolumab, and avelumab across solid tumor indications including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, and head and neck cancer. Phase 2 data reported at the 2026 ASCO Annual Meeting showed a 33% objective response rate and 67% disease control rate in doublet checkpoint inhibitor-refractory metastatic melanoma. A clinical trial collaboration and supply agreement with Merck KGaA provides avelumab (Bavencio) for the NSCLC combination cohort.
Aulos was launched in January 2021 as a joint venture between Apple Tree Partners (ATP), which provided a $40 million Series A and a $20 million extension in August 2023 (totaling $60 million in funding), and Biolojic Design, which contributed the AI antibody design platform. The company is headquartered in Larkspur, California, operates with 1–10 employees, and is wholly backed by ATP. Its business model is pre-revenue and clinical-development oriented, with planned future revenue generation through either out-licensing transactions with pharmaceutical partners or an independent commercial launch contingent on registrational trial success.
Aulos Bioscience firmographics
Firmographics- Name
- Aulos Bioscience
- Legal name
- Aulos Bioscience Inc.
- Website
- https://aulosbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), an AI-designed monoclonal antibody that redirects IL-2 toward anti-tumor immune activation while avoiding Treg expansion and IL-2 toxicities, currently in Phase 2 trials for solid tumors.
- Ownership category
- akta.pro rank
Aulos Bioscience industry classification
Industry- Product category
- Immuno-oncology therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
- akta.pro secondary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where Aulos Bioscience is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Aulos Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical-stage biotech company developing IL-2 therapeutics for solid tumor cancers. Revenue will be generated through future product sales upon regulatory approval.
- Pharmaceutical Partnerships: Strategic collaborations and licensing agreements with pharmaceutical companies for development and commercialization rights. The company has clinical trial collaboration and supply agreements with Merck KGaA.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Aulos Bioscience product offering
Product offeringCore offering
Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), a computationally designed human IgG1 monoclonal antibody that binds to the CD25-binding portion of interleukin-2 (IL-2). It redirects IL-2 activity toward immune activation (effector T cells and NK cells) and away from immune suppression (regulatory T cells), while avoiding the vascular leak syndrome and pulmonary edema associated with conventional IL-2 therapy. The company is advancing this single lead candidate through Phase 1/2 clinical trials for solid tumor cancers including melanoma and non-small cell lung cancer (NSCLC).
Product overview
Aulos Bioscience is developing a single core product candidate, imneskibart (AU-007), an IL-2 redirecting antibody therapeutic for solid tumor cancers. The company was founded by Biolojic Design and Apple Tree Partners to develop this AI-designed monoclonal antibody through clinical trials. The product is currently in Phase 1/2 clinical development with multiple expansion cohorts studying the antibody alone and in combination with aldesleukin, nivolumab, and avelumab for treatment of melanoma, NSCLC, and renal cell carcinoma.
Differentiator
Problem solved
Functional benefit
Products and services
- Imneskibart (AU-007) A human IgG1 monoclonal antibody designed using artificial intelligence by Biolojic Design that is highly selective to the CD25-binding portion of interleukin-2 (IL-2). It redirects IL-2 to reinforce anti-tumor immune effects by preventing IL-2 from binding to trimeric receptors on regulatory T cells while allowing IL-2 to bind and expand effector T cells and NK cells. Being developed for treatment of solid tumor cancers including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, both as monotherapy and in combination with aldesleukin, nivolumab, and avelumab.
Quantifiable outcome
- 33% objective response rate (ORR) and 67% disease control rate in doublet CPI-refractory metastatic melanoma patients receiving triplet regimen (imneskibart + low-dose aldesleukin + nivolumab)
- +5 more outcomes
Companies that use Aulos Bioscience
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Aulos Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Aulos Bioscience partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Merck KGaA, Darmstadt, Germany (Ares Trading S.A.)coreClinical trial collaboration and supply agreement for use of avelumab (anti-PD-L1 antibody with Fc effector function) in combination with AU-007 and low-dose subcutaneous aldesleukin in a Phase 2 cohort for second-line treatment of PD-L1+ non-small cell lung cancer. Avelumab is approved for multiple tumor types and is the only approved PD-L1/PD-1 antibody with Fc effector function.
- Biolojic DesigncoreCo-founding strategic partner and technology provider. Biolojic Design, founded by Yanay Ofran, provides the AI/computationally-designed antibody platform that designed imneskibart (AU-007). Yanay Ofran serves as co-founder and chief scientific officer of Aulos. The company was founded by Biolojic Design and ATP.
- TevaminorCooperation agreement with Teva for research and development activities. Teva is a multinational pharmaceutical company.
- Nektar TherapeuticsminorCooperation agreement with Nektar Therapeutics for research and development activities. Nektar is a biopharmaceutical company.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Aulos Bioscience competitors and assessment
Company assessmentDirect peers
- Nektar Therapeutics: Direct competitor in the IL-2 immuno-oncology space. Nektar developed bempegaldesleukin, a PEGylated IL-2 agonist, and is already an Aulos research partner, providing highly relevant comparability on mechanism and clinical development challenges.
- Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated IL-2 and IL-12 prodrugs (PREDATOR platform) for solid tumors. Directly comparable as a smaller, IL-2-focused immuno-oncology competitor with tumor microenvironment-selective approaches.
- Medicenna Therapeutics: Develops engineered IL-2 and IL-4 'super-kines' for immuno-oncology. Comparable as a clinical-stage, IL-2 pathway-focused biotech pursuing differentiated cytokine-based mechanisms in solid tumors.
- Xilio Therapeutics: Clinical-stage biotech developing tumor-activated IL-2 and IL-15 molecules and checkpoint inhibitors. Closely comparable to Aulos in stage, size, and focus on localized IL-2 immune activation in solid tumors.
Emerging players
- Cullinan Oncology: Clinical-stage oncology company with a pipeline spanning EGFR, CLDN18.2, and immune-engaging assets. Comparable as a similarly-sized immuno-oncology biotech with a multi-asset portfolio strategy.
- Compugen: AI-driven predictive computational biology company developing immuno-oncology targets. Comparable as a peer leveraging computational platforms to discover novel immuno-oncology targets, though at an earlier and broader discovery stage.
Broad incumbents
- Pfizer: Global pharmaceutical company with deep immuno-oncology portfolio and historical IL-2 program work. Comparable as a broad incumbent whose checkpoint inhibitor (via Bavencio/avelumab partnership) and oncology expertise frame AU-007's commercial landscape.
- Roche: Global pharma with leading oncology franchise including checkpoint inhibitors (Tecentriq) and IL-2 pathway research. Comparable as a broad incumbent defining the immuno-oncology competitive and partnership landscape.
- Bristol-Myers Squibb: Major immuno-oncology incumbent with Opdivo (nivolumab) and Yervoy, the backbone CPI agents in Aulos's combination regimens. Comparable as the established leader in CPI-refractory melanoma treatment that AU-007 is positioning to follow.
- Merck KGaA: Existing Aulos partner supplying avelumab (Bavencio) for NSCLC combination trials. Comparable as a broad oncology incumbent and validation partner whose commercial reach could enable global launch.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Aulos Bioscience social profiles
Digital presenceAulos Bioscience compliance and trust
Trust signalCompliance1 record
Aulos Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aulos Bioscience leadership team
Management profileNumber of profiles
Profiles10 records
Aulos Bioscience funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aulos Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aulos Bioscience
What does Aulos Bioscience do?
Aulos Bioscience is a clinical-stage immuno-oncology company developing imneskibart (AU-007), a computationally designed human IgG1 monoclonal antibody that binds to the CD25-binding portion of interleukin-2 (IL-2). It redirects IL-2 activity toward immune activation (effector T cells and NK cells) and away from immune suppression (regulatory T cells), while avoiding the vascular leak syndrome and pulmonary edema associated with conventional IL-2 therapy. The company is advancing this single lead candidate through Phase 1/2 clinical trials for solid tumor cancers including melanoma and non-small cell lung cancer (NSCLC).
Is Aulos Bioscience a public or private company?
Aulos Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aulos Bioscience founded?
Aulos Bioscience was founded in 2021. It employs 1 to 10 people.
Where is Aulos Bioscience based?
Aulos Bioscience is headquartered in Cambridge, United States, in the North America region.
How does Aulos Bioscience make money?
Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are pharmaceutical Partnerships.
Who are Aulos Bioscience's main competitors?
Direct peers on record are Nektar Therapeutics, Werewolf Therapeutics, Medicenna Therapeutics and Xilio Therapeutics. Emerging players are Cullinan Oncology and Compugen. Broad incumbents are Pfizer, Roche, Bristol-Myers Squibb and Merck KGaA.
Does Aulos Bioscience have an API?
No public API is recorded for Aulos Bioscience.
What industry is Aulos Bioscience in?
Aulos Bioscience's product category is Immuno-oncology therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.